Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,251Revenue $M18,676Net Margin (%)27.2Z-Score2.3
Enterprise Value $M112,391EPS $6.6Operating Margin %31.4F-Score6
P/E(ttm))21.2Cash Flow Per Share $6.7Pre-tax Margin (%)28.2Higher ROA y-yY
Price/Book4.310-y EBITDA Growth Rate %11.0Quick Ratio4.0Cash flow > EarningsY
Price/Sales5.55-y EBITDA Growth Rate %8.7Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %20.5ROA % (ttm)7.7Higher Current Ratio y-yN
Dividend Yield %1.7Insider Buy (3m)1ROE % (ttm)23.0Less Shares Outstanding y-yN
Payout Ratio %33.0Shares Outstanding M757ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNDaniel Loeb 2014-06-30 Buy 0.65%$110.29 - $126.07
($115.72)
$ 137.8319%New holding, 450000 sh.450,000
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 137.8319%New holding, 9938 sh.9,938
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 137.8319%Add 85.28%60,335
AMGNJohn Hussman 2014-06-30 Reduce-0.93%$110.29 - $126.07
($115.72)
$ 137.8319%Reduce -66.67%50,000
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 137.8314%Add 37.87%32,565
AMGNDodge & Cox 2014-03-31 Reduce$113.48 - $127.47
($121.04)
$ 137.8314%Reduce -22.59%105,757
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 137.8314%Reduce -9.42%32,161,744
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 137.8314%Reduce -6.4%8,213,855
AMGNJohn Hussman 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 137.8314%Reduce -14.29%150,000
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 137.8314%Sold Out0
AMGNRay Dalio 2014-03-31 Sold Out -0.01%$113.48 - $127.47
($121.04)
$ 137.8314%Sold Out0
AMGNJoel Greenblatt 2013-12-31 Buy 0.06%$106.28 - $118.688
($113.73)
$ 137.8321%New holding, 23170 sh.23,170
AMGNRay Dalio 2013-12-31 Buy 0.01%$106.28 - $118.688
($113.73)
$ 137.8321%New holding, 7513 sh.7,513
AMGNVanguard Health Care Fund 2013-12-31 Reduce-0.76%$106.28 - $118.688
($113.73)
$ 137.8321%Reduce -18.43%8,775,155
AMGNJohn Hussman 2013-12-31 Reduce-0.45%$106.28 - $118.688
($113.73)
$ 137.8321%Reduce -30%175,000
AMGNJohn Hussman 2013-09-30 Add0.3%$95.81 - $117.521
($108.55)
$ 137.8327%Add 25%250,000
AMGNMario Gabelli 2013-09-30 Add$95.81 - $117.521
($108.55)
$ 137.8327%Add 26.95%22,420
AMGNPRIMECAP Management 2013-09-30 Reduce-0.22%$95.81 - $117.521
($108.55)
$ 137.8327%Reduce -4.11%35,812,225
AMGNRay Dalio 2013-09-30 Sold Out -0.07%$95.81 - $117.521
($108.55)
$ 137.8327%Sold Out0
AMGNDodge & Cox 2013-09-30 Reduce-0.01%$95.81 - $117.521
($108.55)
$ 137.8327%Reduce -38.73%160,052
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Joel Greenblatt 2014-06-309,93800.02New Buy
AMGN Daniel Loeb 2014-06-30450,0000.060.65New Buy
AMGN Mario Gabelli 2014-06-3060,3350.010.04+85.28%
AMGN PRIMECAP Management 2014-06-3031,853,8444.214.1-0.96%
AMGN Vanguard Health Care Fund 2014-06-308,049,4551.062.5-2%
AMGN Dodge & Cox 2014-06-3085,8570.010.01-18.82%
AMGN John Hussman 2014-06-3050,0000.010.45-66.67%
Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.977.7view
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.298.28view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8322.16view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7723.32view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4524.79view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.698.79view
HENDERSON REBECCA MDirector 2014-02-13Sell20,000$123.5311.58view
AMGEN INC10% Owner 2013-12-17Buy272,142$71869view
Balachandran MadhavanEVP, Operations 2013-09-04Sell18,000$112.7622.23view
BALTIMORE DAVIDDirector 2013-08-28Sell4,582$109.6625.69view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
    Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
    Amgen Inc: As Good as It Gets? Feb 20 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Mario Gabelli Comments on Amgen Inc. Jan 06 2014 
    The Gabelli Asset Fund Shareholder Commentary - Third Quarter Jan 06 2014 
    38 Stocks with Higher Dividends Dec 23 2013 
    Vanguard Health Care Fund’s Top Third Quarter Holdings Oct 31 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    PRIMECAP Trims Top Biotechs and More Aug 30 2013 

    More From Our Partners
    Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN) Aug 27 2014 - BENZINGA

    More From Other Websites
    Who are Amgen Inc.'s (AMGN) main competitors? Aug 27 2014
    Why Amgen (AMGN) Stock Hit a One-Year High Today Aug 27 2014
    [$$] Amgen Heart Drug Gets FDA Priority Aug 27 2014
    FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart... Aug 27 2014
    9:15 am Amgen: FDA grants Amgen priority review designation for Ivabradine for the treatment of... Aug 27 2014
    [video] Gilead 'the drug story': Cramer Aug 25 2014
    Amgen Upgraded to Strong Buy Aug 22 2014
    Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Aug 21 2014
    Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Aug 21 2014
    Announcement of top-line results from Phase 3 FOCUS Trial of Carfilzomib (ONO-7057), a proteasome... Aug 20 2014
    Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Aug 19 2014
    A New Cannabinoid-based Arthritis Therapy in the Making Aug 19 2014
    Amgen Names Elliott M. Levy, M.D., Senior Vice President, Global Development Aug 19 2014
    [video] Hot biotech drugs Aug 19 2014
    Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company Aug 19 2014
    Nasdaq hits highest level since March 2000 Aug 18 2014
    Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of... Aug 18 2014
    Amgen thyroid drug succeeds in late-stage trial Aug 18 2014
    Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of... Aug 18 2014
    Amgen Market Value Playing Catch-Up to Shares: Chart of the Day Aug 14 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK